Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Medicare targets 15 more drugs for price negotiations
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
clinicaltrialsarena
4m
Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe
Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.
The Financial Express
3h
Blockbuster weight loss drug Tirzepatide coming to India soon: Benefits, weight loss potential, and side effects
This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...
2d
on MSN
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
2d
on MSN
Ozempic, Wegovy and other drugs are among 15 selected for Medicare's price negotiations
Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback